Sumary of CAR-T treatment does not increase AKI or death risk in patients with CKD:
- Renal outcomes after chimeric antigen receptor T-cell (CAR-T) therapy: A single-center perspective.
- Back to Healio Patients with chronic kidney disease are not at an increased risk for AKI or death after chimeric antigen receptor T-cell therapy, according to a speaker at ASN Kidney Week.
- “A paucity of data exists of renal outcomes in patients treated with [chimeric antigen receptor T-cell] CAR-T, especially with CKD,” Rehan Ansari, MD, of Case Western Reserve University in Cleveland, and colleagues wrote.
- “In conclusion, we also found a low incidence of AKI and CAR-T therapy, with no correlation with baseline renal function.